Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunling Du

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The American Journal of Cardiology|July 26, 2014
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)Daniel Gaudet, Dean J Kereiakes, James M McKenney, et al.
The Journal of School Health|August 22, 2006
Using school staff to establish a preventive network of care to improve elementary school students' control of asthmaJean-Marie Bruzzese, David Evans, Sandra Wiesemann, et al.
The New England Journal of Medicine|March 23, 2012
Effect of a monoclonal antibody to PCSK9 on LDL cholesterolEvan A Stein, Scott Mellis, George D Yancopoulos, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
European Heart Journal|August 31, 2016
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Journal of Medicinal Chemistry|March 22, 2024
Discovery of Novel 5,6-Dihydro-4<i>H</i>-pyrido[2,3,4-<i>de</i>]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 KinasesLeifu Yang, Yaxin Li, Yunling Du, et al.
Circulation. Cardiovascular Genetics|September 17, 2015
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyPaul N Hopkins, Joep Defesche, Sigrid W Fouchier, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The American Journal of Cardiology|July 26, 2014
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)Daniel Gaudet, Dean J Kereiakes, James M McKenney, et al.
The Journal of School Health|August 22, 2006
Using school staff to establish a preventive network of care to improve elementary school students' control of asthmaJean-Marie Bruzzese, David Evans, Sandra Wiesemann, et al.
The New England Journal of Medicine|March 23, 2012
Effect of a monoclonal antibody to PCSK9 on LDL cholesterolEvan A Stein, Scott Mellis, George D Yancopoulos, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
European Heart Journal|August 31, 2016
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Journal of Medicinal Chemistry|March 22, 2024
Discovery of Novel 5,6-Dihydro-4<i>H</i>-pyrido[2,3,4-<i>de</i>]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 KinasesLeifu Yang, Yaxin Li, Yunling Du, et al.
Circulation. Cardiovascular Genetics|September 17, 2015
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyPaul N Hopkins, Joep Defesche, Sigrid W Fouchier, et al.
Pageof 3